Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Sequenom Inc. Stories

2012-02-22 17:10:00

SAN DIEGO, Feb. 22, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it has filed a motion for preliminary injunction against Aria Diagnostics ("Aria") to stop Aria from making, using, selling or offering for sale, importing or exporting, infringing tests for detecting fetal chromosomal aneuploidy, such as Aria's Harmony Prenatal Test(TM), pending the ultimate resolution of the litigation....

2012-02-22 06:30:00

SAN DIEGO, Feb. 22, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced it will report financial results for the fourth quarter and full-year 2011 after closing of the NASDAQ Global Market on Wednesday, March 7, 2012. A conference call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and other members of senior management will take place on the same day at 5:00pm, ET (2:00pm PT) and will...

2012-02-08 06:30:00

SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that its wholly-owned subsidiary, the Sequenom Center for Molecular Medicine (Sequenom CMM), has expanded the application of its recently launched laboratory-developed test (LDT). The Company also announced it has rebranded the test under the name MaterniT21 PLUS, which includes the detection of trisomies 18 and 13 in...

2012-02-02 15:00:00

SAN DIEGO, Feb. 2, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that a new publication of an independent multi-center study on Sequenom Center for Molecular Medicine's MaterniT21(TM) laboratory-developed test (LDT) appears today in the online issue of Genetics in Medicine. The study demonstrated the LDT can detect fetal trisomy 21, 18 and 13 with high accuracy from a maternal blood sample and will...

2012-01-25 15:10:00

SAN DIEGO, Jan. 25, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM) today announced the completion of an underwritten public offering of 14,950,000 shares of its common stock, including 1,950,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offered by Sequenom at a price to the public of $4.15 per share. The gross proceeds to Sequenom from this offering were approximately $62.0 million, before...

2012-01-23 07:50:00

VANCOUVER, British Columbia, Jan. 23, 2012 /PRNewswire-Asia/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and Equity Research for the following companies: SandRidge Energy (NYSE:SD), NVIDIA (NASDAQ:NVDA), People's United Financial (NASDAQ:PBCT), Charles Schwab (NYSE:SCHW), MGM Resorts International (NYSE:MGM) and Sequenom (NASDAQ:SQNM). (Logo: http://photos.prnewswire.com/prnh/20111214/HK22486LOGO ) (Read full report by clicking the link below, you may...

2012-01-20 07:45:00

SAN DIEGO, Jan. 20, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM) today announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock, offered at a price to the public of $4.15 per share. The gross proceeds to Sequenom from this offering are expected to be $53.95 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Sequenom. Sequenom has granted the underwriters a 30-day option to...

2012-01-19 15:01:00

SAN DIEGO, Jan. 19, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies & Company, Inc. is acting as sole book-running manager for the offering. The securities described above are being...

2012-01-08 19:00:00

SAN DIEGO, Jan. 8, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced highlights of the Company's 2011 performance and accomplishments, as well as preliminary activities and goals for the first part of 2012. Initial 2011 Performance Results Total revenue growth of approximately 23 percent year-over-year for 2011 (unaudited). Over 21,000 total prenatal and retinal diagnostic tests were billed during...

2012-01-05 06:30:00

SAN DIEGO, Jan. 5, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the 30th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on January 9-12, 2012. Harry F. Hixson, Jr, Ph.D., Chairman and CEO, and Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development, will present on Thursday, January 12, 2012...